Tabalumab Phase III Trial Fails To Meet Primary End-Points In RA Patients
News
Tabalumab, an anti-B Cell Activating Factor (BAFF) monoclonal antibody, which has been designed to treat autoimmune disorders and B-cell malignancies, by Eli Lilly and Company, did not meet its primary ... Read more